| Objective To explore the application efficacy of nedaplatin combined with paclitaxel in neoadjuvant chemotherapy for the patients with locally advanced cervical cancer.Methods Sixty patients with locally advanced cervical cancer, ever treated in our hospital from Sep 2010 to Mar 2013, were randomly divided into the nedaplatin group and the control group, 30 patients in each group.Patients in the nedaplatin group were treated by neoadjuvant chemotherapy with nedaplatin and paclitaxel, while patients in the control group were treated with cisplatin and paclitaxel.The curative effects and adverse reactions of patients between the two groups were compared.Results The short-term total effective rates in the nedaplatin group and the control group were 76.7% and 80.0%, respectively, with no significant difference between them (χ2=0.098, P=0.754).Patients in the two groups both had significantly shorter tumor diameters after chemotherapy than those before chemotherapy (5.3±0.9 vs 3.2±0.6, 5.2±0.8 vs 3.3±0.7; P<0.05).When compared with the control group, the nedaplatin group had lower incidences of stage I~II nausea and vomiting (36.7% vs 70.0%), anemia (16.7% vs 40.0%) and renal function damage (10.0% vs 36.7%), but had higher incidence of stage I~II thrombocytopenia (56.7% vs 30%), and their differences were statistically significant (all P<0.05).Conclusion The neoadjuvant chemotherapy with nedaplatin combined with paclitaxel may have similar curative effects as cisplatin combined with paclitaxel in the treatment of locally advanced cervical cancer, but with less adverse reactions, and it is worthy of clinical promotion. |
